Ishikawa Toshihisa, Nakagawa Hiroshi, Hagiya Yuichiro, Nonoguchi Naosuke, Miyatake Shin-Ichi, Kuroiwa Toshihiko
Omics Science Center, RIKEN Yokohama Institute, 1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama 230-0045, Japan.
Adv Pharmacol Sci. 2010;2010:587306. doi: 10.1155/2010/587306. Epub 2010 Jul 8.
Accumulating evidence indicates that ATP-binding cassette (ABC) transporter ABCG2 plays a key role in regulating the cellular accumulation of porphyrin derivatives in cancer cells and thereby affects the efficacy of photodynamic therapy and photodynamic diagnosis. The activity of porphyrin efflux can be affected by genetic polymorphisms in the ABCG2 gene. On the other hand, Nrf2, an NF-E2-related transcription factor, has been shown to be involved in oxidative stress-mediated induction of the ABCG2 gene. Since patients have demonstrated individual differences in their response to photodynamic therapy, transcriptional activation and/or genetic polymorphisms of the ABCG2 gene in cancer cells may affect patients' responses to photodynamic therapy. Protein kinase inhibitors, including imatinib mesylate and gefitinib, are suggested to potentially enhance the efficacy of photodynamic therapy by blocking ABCG2-mediated porphyrin efflux from cancer cells. This review article provides an overview on the role of human ABC transporter ABCG2 in photodynamic therapy and photodynamic diagnosis.
越来越多的证据表明,ATP结合盒(ABC)转运蛋白ABCG2在调节癌细胞中卟啉衍生物的细胞蓄积方面发挥关键作用,从而影响光动力疗法和光动力诊断的疗效。ABCG2基因的遗传多态性可影响卟啉外排活性。另一方面,NF-E2相关转录因子Nrf2已被证明参与氧化应激介导的ABCG2基因诱导。由于患者对光动力疗法的反应存在个体差异,癌细胞中ABCG2基因的转录激活和/或遗传多态性可能会影响患者对光动力疗法的反应。包括甲磺酸伊马替尼和吉非替尼在内的蛋白激酶抑制剂被认为可能通过阻断ABCG2介导的癌细胞卟啉外排来提高光动力疗法的疗效。本文综述了人类ABC转运蛋白ABCG2在光动力疗法和光动力诊断中的作用。